Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mahasweta Gooptu

Showing results (51-60 of 62) with videos related to

Pageof 7
Sort By:
Blood|July 22, 2021
HLA-haploidentical vs matched unrelated donor transplants with posttransplant cyclophosphamide-based prophylaxisMahasweta Gooptu, Rizwan Romee, Andrew St Martin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 30, 2026
Randomized, Placebo-Controlled Trial of B-Cell Depletion for Prevention of Corticosteroid-Requiring Chronic Graft-Versus-Host DiseaseCorey Cutler, Haesook T Kim, Hassan El Banna, et al.
Blood Advances|February 24, 2026
No clear benefit of cellular therapy consolidation for patients achieving remission after post-HCT AML relapseH Moses Murdock, Haesook T Kim, Katie Maurer, et al.
Blood Advances|October 31, 2025
No clear benefit of cellular therapy consolidation for patients achieving remission after post-HCT AML relapseH Moses Murdock, Haesook T Kim, Katie Maurer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 16, 2025
Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis After Mismatched Unrelated Donor Peripheral Blood Stem Cell TransplantationMonzr M Al Malki, Stephanie Bo-Subait, Brent Logan, et al.
The New England Journal of Medicine|June 21, 2023
Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease ProphylaxisJavier Bolaños-Meade, Mehdi Hamadani, Juan Wu, et al.
Blood Advances|April 30, 2025
Impact of Post-Transplant Cyclophosphamide-Based GVHD Prophylaxis in Patients 70 years and Older: An Update from BMT CTN 1703Sameem M Abedin, Michael J Martens, Javier Bolaños-Meade, et al.
The Journal of Clinical Investigation|March 29, 2022
Expansion, persistence, and efficacy of donor memory-like NK cells infused for posttransplant relapseRoman M Shapiro, Grace C Birch, Guangan Hu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 3, 2025
Improved Patient-Reported Outcomes With Post-Transplant Cyclophosphamide: A Quality-of-Life Evaluation and 2-Year Outcomes of BMT CTN 1703Shernan G Holtan, Javier Bolaños-Meade, Monzr M Al Malki, et al.
Blood Advances|January 26, 2026
Baseline IPSS-M vs Pretransplant Risk Downstaging as Prognostic Determinants in MDS Undergoing Allogeneic TransplantationLuis E Aguirre, Haesook T Kim, Hany Elmariah, et al.
Pageof 7

Showing results (51-60 of 62) with videos related to

Sort By:
Pageof 7
Blood|July 22, 2021
HLA-haploidentical vs matched unrelated donor transplants with posttransplant cyclophosphamide-based prophylaxisMahasweta Gooptu, Rizwan Romee, Andrew St Martin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 30, 2026
Randomized, Placebo-Controlled Trial of B-Cell Depletion for Prevention of Corticosteroid-Requiring Chronic Graft-Versus-Host DiseaseCorey Cutler, Haesook T Kim, Hassan El Banna, et al.
Blood Advances|February 24, 2026
No clear benefit of cellular therapy consolidation for patients achieving remission after post-HCT AML relapseH Moses Murdock, Haesook T Kim, Katie Maurer, et al.
Blood Advances|October 31, 2025
No clear benefit of cellular therapy consolidation for patients achieving remission after post-HCT AML relapseH Moses Murdock, Haesook T Kim, Katie Maurer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 16, 2025
Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis After Mismatched Unrelated Donor Peripheral Blood Stem Cell TransplantationMonzr M Al Malki, Stephanie Bo-Subait, Brent Logan, et al.
The New England Journal of Medicine|June 21, 2023
Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease ProphylaxisJavier Bolaños-Meade, Mehdi Hamadani, Juan Wu, et al.
Blood Advances|April 30, 2025
Impact of Post-Transplant Cyclophosphamide-Based GVHD Prophylaxis in Patients 70 years and Older: An Update from BMT CTN 1703Sameem M Abedin, Michael J Martens, Javier Bolaños-Meade, et al.
The Journal of Clinical Investigation|March 29, 2022
Expansion, persistence, and efficacy of donor memory-like NK cells infused for posttransplant relapseRoman M Shapiro, Grace C Birch, Guangan Hu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 3, 2025
Improved Patient-Reported Outcomes With Post-Transplant Cyclophosphamide: A Quality-of-Life Evaluation and 2-Year Outcomes of BMT CTN 1703Shernan G Holtan, Javier Bolaños-Meade, Monzr M Al Malki, et al.
Blood Advances|January 26, 2026
Baseline IPSS-M vs Pretransplant Risk Downstaging as Prognostic Determinants in MDS Undergoing Allogeneic TransplantationLuis E Aguirre, Haesook T Kim, Hany Elmariah, et al.
Pageof 7